NETs: The First Steps to Treatment

A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.

These seven breast cancer clinical trials are recruiting patients now, spanning early-stage, HR-positive, HER2-positive and triple-negative disease.

Two sisters discover they share a BRCA2 mutation, but choose different paths to manage their breast cancer risk and navigate life as previvors.

A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.